Long-term multicentre study on beta 2-microglobulin removal by PMMA BK membrane

Area of Science:

• Nephrology
• Biomaterials Science
• Clinical Medicine

Background:

• Beta 2-microglobulin (beta 2-M) amyloidosis is a complication of chronic kidney disease.
• Polymethylmethacrylate (PMMA) membranes are used in hemodialysis.
• Optimizing PMMA membrane pore size is crucial for effective beta 2-M removal.

Purpose of the Study:

• To evaluate the clinical significance of a newly designed PMMA membrane (BK membrane) for beta 2-M removal.
• To assess the impact of early versus late introduction of BK membrane hemodialysis on beta 2-M levels and joint pain.
• To determine the long-term efficacy of the BK membrane in chronic hemodialysis patients.

Main Methods:

• A long-term, multi-center clinical study involving 73 chronic hemodialysis patients across 28 centers.
• Patients were divided into four groups based on the timing of BK membrane introduction.
• Plasma beta 2-M concentrations and pain index were monitored throughout the study.

Main Results:

• Plasma beta 2-M levels decreased in all groups using the BK membrane.
• Early introduction of BK membrane hemodialysis led to a greater reduction in plasma beta 2-M compared to later introduction.
• The pain index significantly decreased with continued use of the BK membrane, indicating amelioration of joint pain.

Conclusions:

• Early initiation of hemodialysis with the BK membrane effectively reduces plasma beta 2-M concentrations.
• The BK membrane demonstrates efficacy in ameliorating and potentially preventing joint pain associated with hemodialysis.
• Optimized PMMA membrane technology offers a promising approach for managing beta 2-M related complications in chronic hemodialysis patients.